Outcome measures of phase III anticancer drug trials in China

二维码有效期 120s

作者 Guo Lanwei ^[1] Huang Huiyao ^[2] Yu Yue ^[2] Wang Jun ^[3] Wang Le ^[4] Wang Shuhang ^[2] Wu Dawei ^[2] Fang Yuan ^[2] Jiang Ning ^[2] Zhang Shaokai ^[1] Tang Yu ^[2] Li Ning ^[2] 学术成果认领

作者单位 Department of Cancer Epidemiology and Prevention, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, The Affiliated Cancer Hospital of Zhengzhou University amp; Henan Cancer Hospital, Zhengzhou, Henan 450008, China ^[1] Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China ^[2] National Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China ^[3] Department of Cancer Prevention, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang 310022, China. ^[4]

栏目名称 Correspondence

DOI 10.1097/CM9.0000000000002264

发布时间 2025-02-25

基金项目

Natural Science Foundation of Henan Province Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences